Advances in prostate cancer biomarker research

Poster Session 84

  • Location:
    Room Madrid (Hall B2, level 0)
  • Chairs:
     M. Lazzeri, Florence (IT)
     H.G. Lilja, New York (US)
     T. Steuber, Hamburg (DE)
  • Aims and objectives of this session

    There is an increasing interest in the role of truncated androgen receptors in prostate cancer. These potentially very important biomarkers have been identified in several publications, however scientific consensus has to be reached. In addition, controversies on activated transcription factors as biomarkers will be discussed.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
Prostate cancer biomarkers: What's new?
 H.G. Lilja, New York (US)
* 1064
Delivery of precision medicine in advanced prostate cancer using circulating tumour cells

By: Rhee H.1, Gunter J.2, Javanovic L.2, Williams E.2, Hollier B.2, Nelson C.2, Vela I.1

Institutes: 1Princess Alexandra Hospital/Queensland University of Technology, Dept. of Urology and Australian Prostate Cancer Research Centre – Queensland, Woolloongabba, Australia, 2Queensland University of Technology, Australian Prostate Cancer Research Centre – Queensland, Woolloongabba, Australia

* 1065
Detection of AR-V7 in circulating tumour cells before ADT is a negative prognostic marker in castration-naïve men with metastatic prostate cancer

By: Josefsson A., Damber J-E., Welén K.

Institutes: Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Dept. of Urology, Gothenburg, Sweden

SIK2 is a novel secreted protein associated with a malignant phenotype in prostate cancer

By: Wadhwa K.1, Bon H.2, Holmes K.3, Warren A.4, Whittaker H.5, Kay J.5, Fryer L.2, Neal D.2, Gnanapragasam V.1, Carroll J.3

Institutes: 1Academic Urology Group, Dept. of Urology, Cambridge, United Kingdom, 2Neal Laboratory, Dept. of Uro-Oncology, Cambridge, United Kingdom, 3Carroll Laboratory, Cambridge Institute CRUK, Cambridge, United Kingdom, 4Addenbrooke’s Trust University of Cambridge, Dept. of Pathology, Cambridge, United Kingdom, 5Biomarker Group, Cambridge Institute CRUK, Cambridge, United Kingdom

Expression of pSTAT3 in prostate cancer metastases from different organs

By: Don-Doncow N.1, Marginean F.1, Morrissey C.2, Hellsten R.1, Bjartell A.1

Institutes: 1Lund University Hospital, Dept. of Translational Medicine Malmö, Malmö, Sweden, 2University of Washington, Dept. of Urology, Seattle, United States of America

Intratumoral heterogeneity of mTOR-pathway parameters in prostate cancer

By: Schanz M.1, Hennenlotter J.1, Dlugosch J.1, Kuehs U.1, Dettmer M.2, Schilling D.3, Schwentner C.1, Stenzl A.1, Todenhöfer T.1

Institutes: 1Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, 2Universitätsklinik Bern, Dept. of Pathology, Berne, Germany, 3Isar Klinikum, Dept. of Urology, Munich, Germany

Regenerating islet-derived related protein 4 as candidate of a novel biomarker in castration-resistant prostate cancer patients

By: Teishima J.1, Nagamatsu H.1, Shoji K.1, Yamanaka R.1, Kobatake K.1, Kitano H.1, Goto K.1, Shinmei S.1, Hayashi T.1, Oue N.2, Yasui W.2, Matsubara A.1

Institutes: 1Institute of Biomedical and Health Sciences, Integrated Health Sciences, Hiroshima University, Dept. of Urology, Hiroshima, Japan, 2Institute of Biomedical and Health Sciences, Integrated Health Sciences, Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan

The role of genomic classifier to assess post-operative metastatic risk for prostate cancer patients based on final pathology characteristics

By: Woodlief T.L., Rocco B., Ramharack R., Gnapathi H., Ogaya G., Mouravieve V., Patel V.

Institutes: Florida Hospital, Global Robotics Institute, Celebration, United States of America

A 2-gene panel derived from prostate cancer-enhanced transcripts in whole blood is prognostic for survival and predicts treatment benefit in metastatic castration-resistant prostate cancer

By: Heck M.1, Thalgott M.1, Schmid S.1, Oh W.2, Gong Y.2, Wang L.3, Zhu J.3, Seitz A-K.1, Porst D.1, Höppner M.1, Retz M.1, Gschwend J.1, Nawroth R.1

Institutes: 1Klinikum Rechts der Isar der Technischen Universität Muenchen, Dept. of Urology, Munich, Germany, 2Mount Sinai Hospital, The Tisch Cancer Institute, Dept. of Hematology/Oncology, New York, United States of America, 3Mount Sinai Hospital, The Tisch Cancer Institute, Dept. of Genetic and Genomic Sciences, New York, United States of America

Prostate cancer copy number score predicts metastatic disease

By: Van Den Broeck T.1, Gevaert T.1, Prekovic S.2, Smeets E.2, Helsen C.2, Lambrechts D.3, Boeckx B.3, Joniau S.1, Claessens F.2

Institutes: 1University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 2KU Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium, 3KU Leuven, Laboratory For Translational Genetics, Vesalius Research Center, VIB, Leuven, Belgium

Microseminoprotein-beta expression in different stages of prostate cancer

By: Sjöblom L2, Saramäki O.2, Annala M.2, Leinonen K.2, Nättinen J.2, Tolonen T.3, Wahlfors T.2, Nykter M.2, Bova G.2, Schleutker J.4, Tammela T.1, Lilja H.2, Visakorpi T.2

Institutes: 1Tampere University Hospital, Dept. of Surgery, Tampere, Finland, 2University of Tampere, BioMediTech, Tampere, Finland, 3Fimlab Laboratories, Dept. of Pathology, Tampere, Finland, 4University of Turku, BioMediTech, Tampere, Finland

PD-L1 expression in castration-resistant prostate cancer (CRPC)

By: Fankhauser C.1, Schüffler P.2, Gillessen S.3, Omlin A.3, Hermanns T.1, Poyet C.4, Sulser T.1, Moch H.4, Wild P.J.4

Institutes: 1University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, 2Memorial Sloan Kettering Cancer Center, The Thomas Fuchs Lab, New York, United States of America, 3Cantonal Hospital, St. Gallen, Dept. of Medical Oncology and Hematology, St. Gallen, Switzerland, 4University Hospital Zurich, Institute of Surgical Pathology, Zurich, Switzerland